Cancer immunotherapy is where peptides intersect with the broader oncology pipeline. Coverage here spans peptide vaccines (neoantigen, multipeptide, survivin-targeted), MHC-class-II activators that modulate antigen presentation, T-cell engager peptides, and the mRNA-vaccine engineering work that depends on peptide-encoding sequences.
Lead programs covered on this site: Immutep's eftilagimod alfa, an MHC class II activator heading to ASCO 2026 with lymphocyte activation and survival outcomes data in metastatic cancer; Mount Sinai's April 29 Nature Biotechnology paper on hepatocyte-detargeted mRNA cancer vaccines that more than doubled lymphoma efficacy in mouse models; BioVaxys's MVP-S survivin peptide vaccine with the PESCO Phase 1B/2 acceptance for ASCO 2026 in recurrent ovarian cancer; the BriaCell Bria-IMT and next-generation Bria-OTS+ programs; and the Pharmacy Times Ferry Ossendorp Q&A on antigen-targeted peptide vaccination.
Stories here cover trial readouts, mechanism papers, and the bridge between peptide design and immune activation. See #peptide-vaccine, #neoantigen, and #asco-2026.
A review article published in the International Journal of Peptide Research and Therapeutics in May 2026 consolidates the current state of peptide-based cancer vaccines, covering antigen selection, adjuvant chemistry, and delivery platforms designed to address tumor evolution and immune escape. The review argues that despite persistent challenges around peptide stability and limited immunogenicity, the combination of nanomaterials and adjuvants has significantly enhanced immune response efficiency and targeted delivery — with applications in drug-resistant and metastatic cancers. The piece sits alongside two other May peptide vaccine reviews (WIRES Nanomedicine, Science Advances) and frames the ASCO 2026 peptide-oncology slate (BioVaxys MVP-S, BriaCell Bria-IMT, Evaxion EVX-01) as the clinical pipeline backing the review-paper momentum.
A 2026 Science Advances paper demonstrated that systematically changing the orientation and placement of a single cancer-targeting peptide within a vaccine construct leads to formulations that significantly enhance immune response. One specific vaccine design consistently outperformed others by shrinking tumors, extending animal survival, and generating larger numbers of highly active cancer-killing T-cells. The work is mechanistically important for the broader personalized neoantigen vaccine pipeline (Mount Sinai PGV001, BioNTech autogene cevumeran, Evaxion EVX-01) because peptide-orientation engineering has been an under-systematized variable in current vaccine designs. The findings provide a generalizable engineering principle that could inform second-generation neoantigen vaccine constructs heading into late 2026 and 2027.
A WIRES Nanomedicine and Nanobiotechnology 2026 review by Garland and colleagues synthesizes the materials-science side of peptide-based cancer vaccine development: lipid nanoparticle delivery, dendrimer scaffolds, peptide self-assembly platforms, and adjuvant chemistry. The piece complements the broader review wave by focusing on delivery and formulation rather than antigen selection. Key themes: lipid-nanoparticle-encapsulated peptides show improved bioavailability and immune-cell uptake versus free peptides; self-assembling peptide hydrogels enable sustained antigen release at injection site; CpG and TLR agonist combinations remain the dominant adjuvant approach but with new variants emerging. The review positions peptide vaccines as catching up to mRNA cancer vaccines (BioNTech, Moderna programs) on delivery sophistication.
Pharmacy Times ran a Ferry Ossendorp Q&A on May 5 walking through the mechanistic case for peptide-based cancer vaccines: T cells recognize small peptides presented on the surface of tumor cells, and synthetic peptides matched to tumor antigens can be used to vaccinate the immune system to recognize and target those tumors. Ossendorp's own work showed that knowledge of a tumor's antigen profile combined with peptide vaccination can protect against very aggressive tumors in animal models. The piece sits inside a 2026 peptide-vaccine pipeline with 31 active personalized cancer-vaccine trials registered (more than dendritic-cell or RNA-vaccine platforms), the BioVaxys MVP-S survivin program heading to ASCO 2026, the Greenwich GP2/GLSI-100 FLAMINGO-01 readout, and the BriaCell Bria-IMT Phase 3.
Immutep announced April 22 that an abstract for its lead asset eftilagimod alfa — a soluble LAG-3 protein that activates antigen-presenting cells via MHC class II — has been accepted for poster presentation at ASCO 2026 (May 29–June 2, Chicago). The abstract, titled 'Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients,' adds a non-checkpoint immunotherapy modality to the ASCO 2026 peptide-and-immuno slate alongside Bicycle Therapeutics' Duravelo-2, BriaCell's Bria-IMT, BioVaxys's MVP-S, and Greenwich LifeSciences' GP2 program.
An Icahn School of Medicine at Mount Sinai team reported in Nature Biotechnology on April 29 that hepatocytes actively dampen the immune response to standard mRNA vaccines and that engineering vaccines to avoid hepatocyte expression sharply boosts efficacy. In mice with lymphoma, an mRNA vaccine engineered to silence hepatocyte expression cut tumor burden by more than 50% versus a conventional mRNA vaccine, driven by a stronger killer T-cell response. The finding inverts a longstanding assumption that liver expression is helpful and supplies a generalizable design principle for mRNA cancer vaccines, infectious-disease vaccines, and gene-editing payloads.